Nature Communications (Apr 2021)

Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes

  • Christina M. Bebber,
  • Emily S. Thomas,
  • Jenny Stroh,
  • Zhiyi Chen,
  • Ariadne Androulidaki,
  • Anna Schmitt,
  • Michaela N. Höhne,
  • Lukas Stüker,
  • Cleidson de Pádua Alves,
  • Armin Khonsari,
  • Marcel A. Dammert,
  • Fatma Parmaksiz,
  • Hannah L. Tumbrink,
  • Filippo Beleggia,
  • Martin L. Sos,
  • Jan Riemer,
  • Julie George,
  • Susanne Brodesser,
  • Roman K. Thomas,
  • H. Christian Reinhardt,
  • Silvia von Karstedt

DOI
https://doi.org/10.1038/s41467-021-22336-4
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 19

Abstract

Read online

The high degree of subtype plasticity in small cell lung cancer (SCLC) poses a therapeutic challenge. Here, the authors show that the non-neuroendocrine (non-NE) subtype of SCLC is sensitive to ferroptosis while the neuroendocrine (NE) subtype is vulnerable to TRX anti-oxidant pathway inhibition, and the combination of these two treatments in SCLC circumvents non-NE/NE subtype plasticity.